6:05 PM
 | 
Feb 08, 2013
 |  BC Extra  |  Company News

FDA approves Celgene's pomalidomide

FDA granted accelerated approval to Pomalyst pomalidomide from Celgene Corp. (NASDAQ:CELG) to treat patients with multiple myeloma (MM). The drug is approved for MM patients who have received at least two prior therapies including Velcade bortezomib and Celgene's Revlimid lenalidomide,...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >